FibroBiologics, Inc. Common Stock
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FBLG research report →
Companywww.fibrobiologics.com
FibroBiologics, Inc. , a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing.
- CEO
- Peter O'Heeron
- IPO
- 2024
- Employees
- 13
- HQ
- Houston, DE, US
Price Chart
Valuation
- Market Cap
- $2.20M
- P/E
- -0.13
- P/S
- 0.00
- P/B
- 0.90
- EV/EBITDA
- -0.17
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -767.07%
- ROIC
- -355.67%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-18,646,000 · -67.06%
- EPS
- $-8.40 · -23.53%
- Op Income
- $-16,649,000
- FCF YoY
- -37.82%
Performance & Tape
- 52W High
- $19.80
- 52W Low
- $0.95
- 50D MA
- $2.54
- 200D MA
- $6.64
- Beta
- 1.10
- Avg Volume
- 449.06K
Get TickerSpark's AI analysis on FBLG
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 4, 26 | O'HEERON PETE | other | 92,410 |
| May 4, 26 | Khoja Hamid | other | 61,607 |
| May 4, 26 | Davis Jason | other | 61,607 |
| May 4, 26 | GARCIA RUBEN A | other | 61,607 |
| Mar 4, 26 | Khoja Hamid | buy | 30,000 |
| Mar 4, 26 | O'HEERON PETE | buy | 15,872 |
| Mar 3, 26 | O'HEERON PETE | buy | 18,200 |
| Mar 2, 26 | O'HEERON PETE | buy | 17,428 |
| Mar 2, 26 | Davis Jason | buy | 70,000 |
| Feb 27, 26 | GARCIA RUBEN A | buy | 40,000 |
Our FBLG Coverage
We haven't published any research on FBLG yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate FBLG Report →